SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasing overall survival in patients with castration-resistant prostate cancer whether or not they had received docetaxel therapy. At the ASCO Genitourinary Cancers Symposium Professor Sten Nilsson MD, PhD, a medical oncologist at the Karolinska Institute in Stockholm presented results from the phase III ALSYMPCA study looking at 1.5 year follow up of patients treated with radium compared to those receiving placebo. He discussed his results with AudioMedica.com and assesses the clinical role of this radiopharmaceutical.
CONTACT:
Professor Sten Nilsson MD PhD
Medical Oncologist
Karolinska Institutet
Stockholm, Sweden
SOURCE:
Abstract number: 9
LINK: http://meetinglibrary.asco.org/content/124468-142
